London under threat? How an ESG focus can hold the key to maintaining its dominance May 11, 2021 By Funds Europe
Robert Murphy, managing director at Edison Group, considers the UK’s financial policy post-Brexit now that London is under scrutiny - and says that creating an ESG hub might give the UK a better chance to assert itself as an investment powerhouse.
Following London ‘taking back control’ of its financial services rulebook in January 2021, its position as the financial powerhouse of Europe has come under scrutiny. Lord Hill’s recent listing review looks set to shape financial policy moving forward and, while we still need to see which of his 15 recommendations will be adopted, even if they are all implemented more changes are likely to be needed for London and the UK to keep its head-and-shoulders advantage over its European counterparts.
Britain s sixth-largest bank Virgin Money returned to profit in March after the UK s recovery from the pandemic meant it cut the amount of money it set aside for bad debts.
The group - formerly known as CYBG - reported pre-tax profits of £72million for the six months to March against losses of £7million a year earlier.
The boost largely came after the bank cut impairment costs for bad debts by 83 per cent to £38million, down from £232million last year.
Virgin Money reported pre-tax profits of £72m for the six months to the end of March
However, the share price fell 5 per cent this morning after what analysts described as a mixed bag of results.
MeaTech 3D Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange
USA - English
Share this article
Share this article
NESS ZIONA, Israel, May 3, 2021 /PRNewswire/ MeaTech 3D Ltd. ( MeaTech ) (Nasdaq: MITC) (TASE: MITC), a technology company focused on developing cultured meat production capabilities including its proprietary three-dimensional printing technology, biotechnology processes, and customizable manufacturing processes for slaughter-free real meat manufacturing, today announced that it is initiating a process to voluntarily delist its ordinary shares, no par value (the Ordinary Shares ), from the Tel Aviv Stock Exchange Ltd. (the TASE ).
In accordance with applicable Israeli law and the rules of the TASE, the last day the Ordinary Shares will trade on the TASE will be August 3, 2021, and the Ordinary Shares will be delisted from the TASE on August 5, 2021. Until the last day of trading on the TASE, shareholders will be able to c
The pharma giant said the second half will see a boost in performance
AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine has delivered sales of US$275mln in the first quarter as it made a bullish statement on its outlook.
The pharma giant expects a performance boost in the second half of 2021 as vaccine rollouts and lower infections will reduce the hit of the pandemic on trading.
Chief executive Pascal Soriot reiterated full-year guidance for the pharma giant after first-quarter figures were in line with expectations.
Total revenue for the year is estimated to jump 11-12%, with core earnings per share (EPS) coming in at US$4.75-5.
AstraZeneca reports ‘strong’ Q1 results, forecasts accelerated growth in 2021
Company is ‘well-positioned for a high growth year’, according to analyst
AstraZeneca has reported ‘solid’ first quarter results, as sales of its COVID-19 vaccine take off and the company’s oncology drugs deliver strong growth.
Overall, the British drugmaker saw an increase in product sales of 15% to $7.25bn, with core earnings per share jumping by 55% to $1.63.
Out of those sales, new medicines represented 53% of total revenue globally, compared to 47% in the same period last year.
Growth for its oncology drugs also increased by 20% to $3bn, while its new cardiovascular, renal and metabolism (CVRM) products grew by 19% to just over $1bn.